A Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Filgotinib, With Single Arm Induction and Maintenance, in Pediatric Subjects (8 to <18 Years of Age) With Moderately to Severely Active Ulcerative Colitis
Latest Information Update: 21 Mar 2025
At a glance
- Drugs Filgotinib (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms Galapeduca
- Sponsors Alfasigma
- 14 Mar 2025 New trial record